A new study improves the understanding of how the stomach-dwelling bacterium Helicobacter pylori influences the risk of premalignant and malignant changes in the stomach.
News: Gastrointestinal Cancer Research Program
Cancer Research UK has awarded a 20-million-pound grant (about $26 million U.S.) to a team of international investigators, including Vanderbilt’s James Goldenring, MD, PhD, to study inflammation-related cancers.
A trans-institutional team of researchers at Vanderbilt University Medical Center and Vanderbilt University has received an $11 million Cancer Moonshot grant to build a single-cell resolution atlas to map out the routes that benign colonic polyps take to progress to colorectal cancer.
A drug commonly used to treat type 2 diabetes might help prevent patients from developing liver cancers, according to a recent study by Harvey J. Murff, MD, MPH, and colleagues.
A recent study has linked inflammation-driven carcinogenesis in the colon to loss of an important signaling protein called SMAD4.
Sirtex Medical Ltd. has renewed a grant award to Dan Brown, MD, professor of Radiology and Radiological Sciences and chief of Interventional Oncology, and his Vanderbilt Health colleagues, for a research program designed to treat patients with liver tumors that cannot be addressed with surgery.
Richard Peek, MD, director of the Vanderbilt Digestive Disease Research Center (VDDRC) and chief of the Division of Gastroenterology, Hepatology and Nutrition, has been appointed to serve on the advisory council of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.
James Goldenring, MD, PhD and colleagues have made a fundamental advance in understanding how microtubules are assembled. Their finding, published as an Editor’s Pick last month in the Journal of Biological Chemistry, may lead to new ways to control cancer.
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors with genetic mutations that make them resistant to these anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, or the cancers develop resistance during treatment.